300452 Stock Overview
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 300452 from our risk checks.
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥12.31 |
52 Week High | CN¥15.58 |
52 Week Low | CN¥9.92 |
Beta | 0.29 |
11 Month Change | -1.60% |
3 Month Change | 16.79% |
1 Year Change | -20.58% |
33 Year Change | -5.59% |
5 Year Change | 38.69% |
Change since IPO | 189.75% |
Recent News & Updates
Shareholder Returns
300452 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -1.6% | 1.0% | -0.9% |
1Y | -20.6% | -4.8% | 5.4% |
Return vs Industry: 300452 underperformed the CN Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: 300452 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
300452 volatility | |
---|---|
300452 Average Weekly Movement | 6.7% |
Pharmaceuticals Industry Average Movement | 7.2% |
Market Average Movement | 8.3% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 300452 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300452's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 969 | Zheng Long Yin | www.shanhe01.com |
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. research and development, production, and sale of new pharmaceutical excipients in China. The company provides cellulose, starch, povidone, stearic acid, coating powder, resin, food additive, and other products.
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. Fundamentals Summary
300452 fundamental statistics | |
---|---|
Market cap | CN¥2.86b |
Earnings (TTM) | CN¥160.43m |
Revenue (TTM) | CN¥843.26m |
17.8x
P/E Ratio3.4x
P/S RatioIs 300452 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300452 income statement (TTM) | |
---|---|
Revenue | CN¥843.26m |
Cost of Revenue | CN¥572.25m |
Gross Profit | CN¥271.01m |
Other Expenses | CN¥110.58m |
Earnings | CN¥160.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.69 |
Gross Margin | 32.14% |
Net Profit Margin | 19.03% |
Debt/Equity Ratio | 32.4% |
How did 300452 perform over the long term?
See historical performance and comparison